Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-21 4:30 pm Sale |
2025-02-19 | 13D | Royalty Pharma plc RPRX |
Severgnini Achille G. | 36,001,535 8.300% |
-5,649,635 (-13.56%) |
Filing History |
| 2025-02-12 09:30 am Sale |
2024-12-31 | 13G | Royalty Pharma plc RPRX |
FMR CORP | 26,309,327 5.900% |
-5,274,599 (-16.70%) |
Filing History |
| 2025-02-04 3:45 pm Purchase |
2024-12-31 | 13G | Royalty Pharma plc RPRX |
BLACKROCK INC BLK |
25,445,414 5.700% |
25,445,414 (New Position) |
Filing History |
| 2024-11-08 3:15 pm Sale |
2024-09-30 | 13G | Royalty Pharma plc RPRX |
MORGAN STANLEY MS |
36,517,159 8.200% |
-4,642,590 (-11.28%) |
Filing History |
| 2024-07-29 4:30 pm Purchase |
2024-07-09 | 13D | Royalty Pharma plc RPRX |
Severgnini Achille G. | 41,651,170 13.000% |
41,651,170 (New Position) |
Filing History |
| 2024-02-13 5:13 pm Purchase |
2023-12-29 | 13G | Royalty Pharma plc RPRX |
The Vanguard Group | 37,997,522 8.540% |
2,369,731 (+6.65%) |
Filing History |
| 2024-02-13 10:17 am Purchase |
2023-12-31 | 13G | Royalty Pharma plc RPRX |
GENERAL ATLANTIC PARTNERS LLC | 26,259,141 5.600% |
14,400 (+0.05%) |
Filing History |
| 2024-02-09 3:13 pm Sale |
2023-12-31 | 13G | Royalty Pharma plc RPRX |
MORGAN STANLEY MS |
41,159,749 9.200% |
-2,615,649 (-5.98%) |
Filing History |
| 2024-02-09 09:49 am Sale |
2024-02-08 | 13G | Royalty Pharma plc RPRX |
FMR CORP | 31,583,926 7.099% |
-12,526,439 (-28.40%) |
Filing History |
| 2023-02-13 4:53 pm Purchase |
2022-12-31 | 13G | Royalty Pharma plc RPRX |
GENERAL ATLANTIC PARTNERS LLC | 26,244,741 5.600% |
871 (+0.00%) |
Filing History |
| 2023-02-10 3:21 pm Sale |
2022-12-30 | 13G | Royalty Pharma plc RPRX |
MORGAN STANLEY MS |
43,775,398 9.900% |
-12,235,612 (-21.85%) |
Filing History |
| 2023-02-09 12:31 pm Purchase |
2023-02-09 | 13G | Royalty Pharma plc RPRX |
FMR CORP | 44,110,365 9.999% |
22,030,570 (+99.78%) |
Filing History |
| 2023-02-09 11:32 am Purchase |
2022-12-30 | 13G | Royalty Pharma plc RPRX |
The Vanguard Group | 35,627,791 8.080% |
5,991,226 (+20.22%) |
Filing History |
| 2023-02-09 11:06 am Sale |
2022-12-31 | 13G | Royalty Pharma plc RPRX |
ADAGE CAPITAL PARTNERS GP LLC | 7,000,000 1.590% |
-17,842,715 (-71.82%) |
Filing History |
| 2022-10-04 4:30 pm Sale |
2022-10-04 | 13D | Royalty Pharma plc RPRX |
Giuliani Mario Germano | 43,816,170 10.000% |
-2,500,000 (-5.40%) |
Filing History |
| 2022-08-11 08:30 am Unchanged |
2022-08-09 | 13D | Royalty Pharma plc RPRX |
Giuliani Mario Germano | 46,316,170 10.600% |
0 (Unchanged) |
Filing History |
| 2022-04-05 4:01 pm Unchanged |
2022-04-01 | 13D | Royalty Pharma plc RPRX |
Giuliani Mario Germano | 46,316,170 10.700% |
0 (Unchanged) |
Filing History |
| 2022-02-10 4:43 pm Purchase |
2021-12-31 | 13G | Royalty Pharma plc RPRX |
MORGAN STANLEY MS |
56,011,010 13.000% |
9,866,127 (+21.38%) |
Filing History |
| 2022-02-10 10:44 am Sale |
2021-12-31 | 13G | Royalty Pharma plc RPRX |
ADAGE CAPITAL PARTNERS GP LLC | 24,842,715 5.780% |
-13,871,565 (-35.83%) |
Filing History |
| 2022-02-10 08:37 am Purchase |
2021-12-31 | 13G | Royalty Pharma plc RPRX |
The Vanguard Group | 29,636,565 6.900% |
29,636,565 (New Position) |
Filing History |